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Immunological memory is a key feature of adaptive immunity. It provides the organism 
with long-lived and robust protection against infection. In organ transplantation, memory 
T cells pose a significant threat by causing allograft rejection that is generally resistant 
to immunosuppressive therapy. Therefore, a more thorough understanding of memory 
T cell biology is needed to improve the survival of transplanted organs without com-
promising the host’s ability to fight infections. This review will focus on the mechanisms 
by which memory T cells migrate to the site where their target antigen is present, with 
particular emphasis on their migration to transplanted organs. First, we will define the 
known subsets of memory T cells (central, effector, and tissue resident) and their cir-
culation patterns. Second, we will review the cellular and molecular mechanisms by 
which memory T cells migrate to inflamed and non-inflamed tissues and highlight the 
emerging paradigm of antigen-driven, trans-endothelial migration. Third, we will discuss 
the relevance of this knowledge to organ transplantation and the prevention or treatment 
of allograft rejection.
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introduction
Immunity is the balanced state of having adequate protection against infection, while maintaining 
adequate tolerance to avoid excessive inflammation, allergy, and autoimmune diseases. In most 
vertebrates including humans, the immune system is composed of two principal components: innate 
and adaptive. Relatively non-specific innate immune responses proceed prior to the development of 
more specific adaptive immunity – thus, providing immediate protection against invading microbes. 
However, a more long-lasting and robust protective strategy is needed. Unlike innate immunity, 
adaptive immunity generates immunological memory after an initial response to a pathogen or 
non-self molecules from genetically unrelated individuals (alloantigens). Immunological memory 
provides the organism with a faster and stronger protective response upon reencountering the same 
pathogen. In the organ transplantation setting, however, allo-reactive memory T cells pose a sig-
nificant threat by mediating accelerated, “second-set” rejection and its presence has been associated 
with increased propensity for early rejection (1). Furthermore, when compared to naive T cells, 
memory cells are more resistant to immunosuppressive therapies as their reactivation and expansion 
require less costimulation and are independent of secondary lymphoid organs (SLOs); therefore, 
they are more efficient at driving effector functions that lead to graft injury (2, 3). A more thorough 
understanding of memory T cell biology should provide new insights into graft rejection. In this 
review, we will focus on connecting the well-established memory T cell chemokine-driven migration 
paradigm with new findings in this field, emphasizing the role of cognate antigens present in target 
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tissues. We will also discuss the necessity of and rationale for the 
two complementary mechanisms that underlie memory T cell 
migration.
Memory T cell Subsets and Their 
Circulation Patterns
The heterogeneity of the memory T cell population was first 
recognized approximately two decades ago. As initially stated, 
human peripheral blood memory T cells are comprised of two 
subsets with distinct homing potentials and effector functions. 
CCR7− memory T cells express low levels of the CD62L molecule, 
migrate to inflamed non-lymphoid tissues, and display immediate 
effector function such as IFN-γ production – thus, they earned 
themselves the moniker effector memory (TEM). CCR7+ memory 
T cells, on the other hand, express high levels of CD62L, which 
along with CCR7 is a lymph-node homing receptor, and were 
named central memory (TCM). TCM are mainly found in lymphoid 
tissues and lack immediate effector function; however, they 
produce IL-2 and proliferate extensively upon re-stimulation, 
whereas TEM display less proliferative capacity (4). Subsequently, 
the central and effector memory T cell subset concept was shown 
to have parallels in mice (5, 6). A more recent study indicated 
that fundamental mechanisms of T cell memory in humans and 
mice share much in common (7). Thus, knowledge acquired in 
mouse and human memory studies appears to be interchange-
able. Significant findings in mouse memory studies, therefore, 
have the potential of rapid translation to non-human primates 
and humans (8).
More recently, in-depth studies on local immunity identified 
a new memory T cell subset, tissue-resident memory (TRM), 
which resides in peripheral non-lymphoid tissues long after the 
initial infection has cleared. TRM provide frontline local protective 
immunity when the same pathogen is reencountered at the entry 
site. Although they express low levels of CCR7 and CD62L as do 
TEM, TRM express high levels of local non-lymphoid tissue-homing 
molecules such as CD103 and CD69 (9, 10). TRM do not routinely 
recirculate and mix with memory subsets in other tissues (10), 
which is not surprising, given the fact TRM were initially missed 
in studies investigating the peripheral blood or secondary lymph 
organs (SLOs).
In summary, the three memory subsets (TEM, TCM, and TRM) 
have distinct circulation patterns as a result of their distinct sur-
face chemokine receptor and adhesion molecule expression. TCM 
mainly circulate in lymphoid tissues (lymph nodes, spleen, and 
bone marrow) and blood; TEM can circulate between lymphoid 
tissues and non-lymphoid tissues during steady state conditions 
(although they are largely excluded from lymph nodes) and 
can skew their preference under certain contexts, which will be 
discussed in detail below; TRM only reside in peripheral non-
lymphoid tissues and do not circulate as their counterparts do 
(8). In this review, we will be mainly discussing TEM migration. 
Although there are some studies indicating that TCM proliferation 
and differentiation under both steady and challenged states can 
give rise to TEM and maintain the labile TEM repertoire (11, 12), 
they will not be discussed here.
Cellular Mechanisms Underlying Memory 
T cell Migration
Memory T cells within the circulatory system specifically TEM 
are constantly on the move for the purpose of immune surveil-
lance. Their recruitment to peripheral tissues requires adhesion 
to and transmigration across blood-vessel walls. This adhesion-
migration cascade consists of four continuous steps: slow roll-
ing, adhesion strengthening (firm adhesion), and intraluminal 
crawling followed by paracellular and transcellular migration 
(13). The underlying mechanisms of cascade activation have 
been intensively investigated. Slow rolling along the endothe-
lium under blood flow condition is mediated by L-selectin, 
P-selectin, and E-selectin, which mainly interact with P-selectin 
glycoprotein ligand 1 (PSGL-1). L-selectin is expressed by leu-
kocytes, while P-selectin and E-selectin are mainly expressed by 
inflamed endothelial cells (ECs) (13). It has long been recognized 
that lymphocyte arrest during rolling is rapidly triggered by 
chemokines or other chemoattractants and is mediated by the 
binding of lymphocyte integrins to immunoglobulin superfam-
ily members, such as ICAM1 and VCAM1, expressed by ECs. 
This chemokine-driven paradigm is dependent on signaling in 
T cells via the G-protein Gαi, which is coupled to chemokine 
receptors (14, 15). This process, the molecular details of which 
will be explained in the next section, is largely enhanced where 
local inflammation is established as chemokines and other che-
moattractants are locally upregulated and displayed on ECs by 
binding to glycosaminoglycans (GAGs). It has been shown that 
T cell homing to different peripheral tissues express distinct sets 
of homing molecules, corresponding to the different chemokines 
and adhesion molecules displayed on the endothelium in each 
specific inflamed tissue. Skin-homing T cells mainly express the 
chemokine receptors CCR4 and CCR10, which bind to their 
ligands CCL17 and CCL27 present in the dermis and epidermis, 
respectively (16–18). As migration of CD4 and CD8 T cells to 
the skin follows anatomic demarcations, unique expression of 
chemokine receptors on CD4 and CD8 T cells may reflect their 
preferential skin-migratory capacity, with CCR10-expressing 
CD8 T cells entering the epidermis and CCR4-expressing CD4 
T cells accessing the dermis (17–19). Distinctively, gut-homing T 
cells express CCR9 and are attracted by the CCR9 ligand CCL25 
expressed by intestinal epithelial cells (20).
Initial studies have indicated that the increased recruit-
ment of T lymphocytes during inflammation is not necessarily 
antigen-specific as both antigen-specific and bystander memory 
T cells accumulate in inflamed peripheral tissues. However, the 
antigen-specific T cell population is preferentially retained and 
activated, while the bystander T cell number gradually declines to 
a background level and they retain a phenotypically inactive state 
(21, 22). In a recent study, using a B6-OVA to B6 transplant model 
where one single antigenic difference between the donor and 
recipient exists, it has been shown that cognate antigen presence 
is necessary for driving antigen-specific memory T cell migration 
into the peripheral tissue, irrespective of whether acute inflam-
mation is present or not, followed by the migration of bystander 
T cells (23). The entry of the former was not dependent on Gαi, as 
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it was not inhibited by pertussis toxin, while the entry of the latter 
was dependent on Gαi-coupled chemokine receptors. Bystanders 
would migrate into the tissue only if antigen-specific T cells were 
already present in the tissue where they presumably cause local 
inflammation and induce chemokine production. This emerging 
Ag-driven memory T cell migration paradigm is also true in 
an autoimmune context where inflammation is minimal at the 
initial stages of T cell accumulation in the pancreatic islets. Until 
then, it had been widely believed that islet infiltrating T cells in 
diabetic mice are composed of both islet antigen-specific as well 
as bystander T cells, and the heterogeneous recruitment was 
driven by inflammatory chemokines (24). However, in a study 
where TCR retrogenic mice were used, it was shown that only 
islet antigen-specific T cells accumulate in the pancreatic islets 
while bystander T cells do not even after the accumulation of 
antigen-specific T cells. In addition, islet Ag-specific T cell entry 
did not necessarily cause diabetes since only diabetogenic T cell 
infiltration caused diabetes while non-diabetogenic autoantigen-
specific T cells did not. Therefore, the authors of this study con-
cluded that islet antigen specificity mediated a cell-autonomous 
and tightly regulated event and was the key for pancreatic islet 
accumulation (25). In later studies, Calderon et al. demonstrated 
that CD4 TCR-transgenic T cells that are specific to islet antigens 
enter pancreatic islets in a manner that is not dependent on 
Gαi-coupled chemokine receptor signaling (26). The entry of 
bystander T cells that are not specific to islet antigens, however, 
was driven by the subsequent wave of chemokines induced by 
IFNg secreted by the islet antigen-specific T cells (27). Moreover, 
it has been shown that both dendritic cells (DCs) and ECs can 
present cognate antigen to memory T cells, conferring the T cell 
transmigration driving force in the contexts of both transplanta-
tion and autoimmunity (23, 26).
To summarize, Gαi-dependent chemokine receptor signaling 
and cognate antigen-engaged TCR signaling are two comple-
mentary pathways underlying memory T cell migration, as they 
both trigger downstream integrin activation, e.g., LFA-1 and 
VLA-4 (28, 29). Integrin conformation change and clustering 
are essential for memory T cell migration, and LFA-1 or VLA-4 
blockade results in significant reduction in T cell migration (30). 
The chemokine receptor and TCR-driven migration paradigms 
may be differentially required at different stages of infiltration 
process, as antigen recognition seems to be key for early T cell 
infiltration, while chemokine signaling comes into play at a later 
stage (23, 25, 31). In the next section, we will discuss the intracel-
lular events that underlie these two pathways that trigger integrin 
activation in T cells.
Molecular Mechanisms Underlying 
Memory T Cell Migration
Understanding the molecular mechanisms responsible for T 
cell migration is important for identifying targets to block T cell 
entry into non-lymphoid tissues in pathologic states such as 
autoimmunity and graft rejection. Careful dissection of the intra-
cellular signaling pathways triggered by chemokine receptors 
versus antigen receptors would also pave the way for specifically 
blocking antigen-dependent migration of T cells while sparing 
chemokine-driven migration. Since the latter appears to be the 
main pathway of T cell migration to sites of microbial infection, 
selectively blocking the former could help treat patients with 
autoimmunity or organ transplant rejections without increasing 
the risk of infection. Therefore, in this section, we will discuss in 
detail how signaling molecules triggered by chemokine receptors 
differ from those triggered by antigen receptors.
As noted previously, integrin activation is essential for T 
cell arrest and firm adhesion on blood vessel walls, which are 
critical steps that trigger memory T cell transmigration across 
the endothelium and into peripheral tissues. There are two well-
known modalities of integrin activation: conformational changes 
leading to increased affinity of individual integrin molecule and 
lateral mobility (clustering) of the integrin molecules contribut-
ing to an overall enhanced cell avidity (Figure 1) (32). Structural 
studies of LFA-1, a common integrin involved in cell adhesion 
and migration, indicated that integrins dynamically equilibrate 
in three distinct conformational states, which are designated as 
folded, extended-closed, and extended-open conformations. 
Both folded and extended-closed integrins display relatively low 
affinity, while extended-open integrin affinity is 103–104-fold 
higher. These integrin conformational changes are consequences 
of inside-out signaling: signals that are first triggered by a recep-
tor on the cell surface (outside-in) but then signal from inside the 
cell (inside-out) to activate integrin molecules (33).
There are mainly two types of receptors that trigger the signals 
involved in integrin conformational changes, namely G protein-
coupled chemokine receptors that bind chemokines such as 
CCL19, CCL21, or CXCL12, and lymphocyte receptors for anti-
gen (TCRs and BCRs) with some influence from costimulatory 
receptors (35, 36). In the chemokine-signaling cascade, dozens 
of signaling proteins have been implicated in regulating distinct 
aspects of integrin activation (conformation change, structural 
stabilization, etc.). Most notably, both rap and rho have been 
validated in transducing signals in the chemokine-mediated 
integrin activation pathway. Rap and rho are small GTP binding 
proteins belonging to the ras superfamily. Distinctly, rap and rho 
each regulate different signal modules, leading to specific control 
of integrin affinity (37). The rap isoform Rap1A is downstream of 
G protein-coupled receptor (GPCR)-induced rapid intracellular 
calcium influx and activation of phospholipase C (PLC), and its 
activation is directly regulated by RAPGEF2, whose activity is 
controlled by PLC-triggered further up-regulation of intracel-
lular calcium and increased intracellular diacylglycerol (DAG) 
(38). RapL is a binding protein of Rap1A, and its overexpression 
enhances LFA-1 clustering and adhesion (39). The mechanism via 
rho-module is less well-defined, although a role of rho isoform 
RhoA in LFA-1 activation has been identified many years before 
(40). Protein kinase C (PKC) isozyme, ζPKC is probably one of 
the candidates, as it directly interacts with RhoA and has been 
shown to be involved in LFA-1 clustering (41, 42).
As the TCR-driven T cell migration paradigm has been 
gradually emphasized over the past decade, here, we will 
discuss TCR-mediated integrin activation in detail (Figure  1). 
TCR engagement-mediated integrin activation facilitates T cell 
adhesion to MHC-bearing antigen presenting cells (APCs), 
stabilizing the T-APC conjugates. The interfaces are referred to 
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as immunological synapses (43). The immunological synapse 
is characterized by the formation of a supramolecular adhesion 
complex (SMAC), which is comprised of a central concentric 
ring (c-SMAC) of TCR-CD3 and costimulatory receptors, and a 
peripheral concentric ring (p-SMAC) of LFA-1 and the cytoskel-
etal protein talin. The stabilization of this dynamic structure is 
correlated with full T cell activation and effector T cell function 
(44, 45). Integrin activation initiated by TCR signaling occurs 
within minutes following T-cell stimulation and the underlying 
intracellular mechanisms have been extensively investigated. 
The initiation of integrin activation signaling cascades by TCR-
proximal signaling events are mediated by the linker for activa-
tion of T cells (LAT) adapter protein, as LAT-deficient T cells 
show impaired TCR signaling and arrested T cell development. 
LAT is a substrate of the tyrosine kinase activated following TCR 
engagement (46). LAT can bind or recruit multiple signaling 
proteins, such as tyrosine kinase Itk and PLC-γ1, and both these 
two LAT-associate proteins play critical roles in TCR-mediated 
integrin activation, possibly by facilitating optimal PLC-γ1 
phosphorylation and activation (29). PLC-γ1 is shown to be 
specifically involved in the TCR inside-out signaling to integrin, 
rather than the chemokine signaling to integrin (47). Although 
the indispensable role of PLC-γ1 in TCR-integrin signaling has 
been established, the mechanism how PLC-γ1 regulate integrin 
activation remains elusive (48). Additionally, SLP-76 is recruited 
to the LAT complex upon TCR stimulation via the adapter 
protein GADS (49). SLP-76 is an adapter protein not only regu-
lating PLC-γ1 activation but also recruiting another important 
adapter protein, adhesion and degranulation promoting adapter 
protein (ADAP), involved in the TCR-integrin signaling cascade 
(50, 51). Adapter ADAP is a hematopoietic cell-specific protein, 
mainly expressed in mast cells and T cells. It has recently been 
established that ADAP regulates integrin-mediated adhesion 
in T cells (52). Genetic deficiency of ADAP results in impaired 
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FiGURe 1 | TCR-mediated integrin activation inside-out signaling. This figure outlines the key mediators in the TCR signaling-mediated integrin (LFA-1) 
activation pathway. ADAP and SKAP1 are two adaptor proteins involved in this pathway, functioning by synergistically recruiting RapL–Rap1–GTP complex to the 
integrin cytosolic tail and leading to integrin confirmation changes and membrane clustering [modified from Ref. (34)].
proliferative responses and decreased effector functions in T 
cells, thus leading to prolonged allograft survival (53). In T cells, 
ADAP is constitutively associated with another adapter partner, 
namely, SKAP55/SKAP1 (Src kinase-associated adapter protein 
of 55 kDa), which is prominently expressed in T cells. The inter-
action involves the SH3 domain of SKAP1 and the proline-rich 
region in ADAP (54, 55). The ADAP/SKAP1 signaling module 
regulates TCR-mediated integrin activation through plasma 
membrane recruitment of activated Rap1 (56). Importantly, 
SKAP1 has been shown to have an indispensable role in LFA-1 
clustering on T cells (57). RapL (regulator of cell adhesion and 
polarization enriched in lymphoid tissues), one of the binding 
partners of Rap1, is indicated to bind to the N-terminus of SKAP1 
via its C-terminal SARAH domain (58). This finding is indica-
tive of the underlying mechanism by which the ADAP/SKAP1 
signaling module recruits RapL–Rap1 complex to the membrane. 
Furthermore, RIAM (Rap1–GTP-interacting adapter molecule) 
is another important adapter protein, which links Rap1 and talin, 
which is the most common cytoplasmic integrin-associated 
actin-binging protein. Talin is proposed to be the “final common 
step” in integrin activation, both in chemokine-mediated and 
TCR-mediated integrin activation (29).
Relevance to Organ Transplantation
In transplantation, allo-reactive memory T cells contribute to 
both acute and chronic rejection; therefore, they pose a significant 
barrier to graft acceptance (59). Allo-reactive memory T cells 
are either pre-existing or de novo generated (60). Pre-exposure 
to allo-antigen (such as pregnancy, transfusion, and previous 
organ transplants) is one reason but not the only reason for 
pre-existence of allo-reactive memory T cells (61). Many studies 
have shown that memory T cells widely display cross-reactivity, 
which is also known as heterologous immunity. A proportion 
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of memory T cells generated against encountered pathogens in 
one’s life can actually show cross-reactivity to alloantigens such 
as the HLA (62, 63). Not only are memory T cells resistant to 
conventional immunosuppressive therapies such as costimula-
tion blockade and chimerism based therapies, but also they are 
relatively resistant to regulation by CD4+ CD25+ FoxP3+ regu-
latory T cells (Treg), which makes them foe of tolerance induction 
and long-term graft survival (64).
Pre-existing donor-reactive memory T cells infiltrate allograft 
rapidly post transplantation and gain effector functions bypassing 
the need for SLOs (3). Since memory T cell graft infiltration is a 
prerequisite for memory T cell-mediated graft rejection, blockade 
of their migration to the graft should be a promising therapy 
in transplantation (65). As previously mentioned, integrin is 
indispensably involved in T cell peripheral migration process. 
However, monoclonal antibodies that target LFA-1, for example, 
block memory and effector T cell migration indiscriminately 
and their combination with a standard immunosuppressive 
regimen increases the chance of developing post transplant 
EBV-associated lymphoproliferative disease, even though they 
significantly attenuate T cell trafficking to graft (66). Monoclonal 
antibodies that target VLA-4 are also associated with reactivation 
of fatal infections. Thus, it is necessary to seek other strategies 
to inhibit memory T cell migration without increasing the risk 
of infection. One such strategy would be to target the inside-out 
signaling pathway downstream of the TCR but not downstream 
of chemokine receptors – thus, inhibiting antigen-driven but not 
chemokine-driven T cell migration. SKAP1, for example, would be 
a candidate target molecule to stop the antigen-driven migration 
of allo-reactive T cells. Additional animal studies should help test 
this possibility with the promise of specifically inhibiting alloreac-
tive memory while sparing “good memories” against pathogens.
Acknowledgment
This work was supported by NIH grant 5R01 AI049466 to FL.
References
1. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak 
JA, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing 
lymphocytes is a manifestation of immunologic memory and correlates 
with the risk of posttransplant rejection episodes. J Immunol (1999) 
163:2267–75. 
2. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection 
by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic 
implications for sensitized transplant recipients. J Immunol (2002) 169:4667–
73. doi:10.4049/jimmunol.169.8.4667 
3. Chalasani G, Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Recall and 
propagation of allospecific memory T cells independent of secondary 
lymphoid organs. Proc Natl Acad Sci U S A (2002) 99:6175–80. doi:10.1073/
pnas.092596999 
4. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of mem-
ory T lymphocytes with distinct homing potentials and effector functions. 
Nature (1999) 401:708–12. doi:10.1038/44385 
5. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of 
effector memory cells in nonlymphoid tissue. Science (2001) 291:2413–7. 
doi:10.1126/science.1058867 
6. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the gen-
eration of memory CD4 T cells in the whole body. Nature (2001) 410:101–5. 
doi:10.1038/35065111 
7. Ahmed R, Akondy RS. Insights into human CD8(+) T-cell memory using 
the yellow fever and smallpox vaccines. Immunol Cell Biol (2011) 89:340–5. 
doi:10.1038/icb.2010.155 
8. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, 
migration patterns, and tissue residence. Annu Rev Immunol (2013) 31:137–61. 
doi:10.1146/annurev-immunol-032712-095954 
9. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 
Memory T cells in nonlymphoid tissue that provide enhanced local immunity 
during infection with herpes simplex virus. Nat Immunol (2009) 10:524–30. 
doi:10.1038/ni.1718 
10. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, et al. 
Dynamic T cell migration program provides resident memory within intes-
tinal epithelium. J Exp Med (2010) 207:553–64. doi:10.1084/jem.20090858 
11. Ely KH, Cookenham T, Roberts AD, Woodland DL. Memory T cell popula-
tions in the lung airways are maintained by continual recruitment. J Immunol 
(2006) 176:537–43. doi:10.4049/jimmunol.176.1.537 
12. Marzo AL, Yagita H, Lefrancois L. Cutting edge: migration to nonlymphoid 
tissues results in functional conversion of central to effector memory CD8 T 
cells. J Immunol (2007) 179:36–40. doi:10.4049/jimmunol.179.1.36 
13. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflam-
mation: the leukocyte adhesion cascade updated. Nat Rev Immunol (2007) 
7:678–89. doi:10.1038/nri2156 
14. Campbell JJ, Qin S, Bacon KB, Mackay CR, Butcher EC. Biology of chemokine 
and classical chemoattractant receptors: differential requirements for adhe-
sion-triggering versus chemotactic responses in lymphoid cells. J Cell Biol 
(1996) 134:255–66. doi:10.1083/jcb.134.1.255 
15. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. 
Chemokines and the arrest of lymphocytes rolling under flow conditions. 
Science (1998) 279:381–4. doi:10.1126/science.279.5349.381 
16. Campbell JJ, O’Connell DJ, Wurbel MA. Cutting edge: chemokine receptor 
CCR4 is necessary for antigen-driven cutaneous accumulation of CD4 T cells 
under physiological conditions. J Immunol (2007) 178:3358–62. doi:10.4049/
jimmunol.178.6.3358 
17. Tubo NJ, McLachlan JB, Campbell JJ. Chemokine receptor requirements for 
epidermal T-cell trafficking. Am J Pathol (2011) 178:2496–503. doi:10.1016/j.
ajpath.2011.02.031 
18. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al. CCL27-
CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 
(2002) 8:157–65. doi:10.1038/nm0202-157 
19. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, et al. 
Different patterns of peripheral migration by memory CD4+ and CD8+ T 
cells. Nature (2011) 477:216–9. doi:10.1038/nature10339 
20. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, Marquez G, 
et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) 
lymphocytes to the small-intestinal mucosa. J Clin Invest (2002) 110:1113–21. 
doi:10.1172/JCI0215988 
21. Chen AM, Khanna N, Stohlman SA, Bergmann CC. Virus-specific and 
bystander CD8 T cells recruited during virus-induced encephalomyelitis. J 
Virol (2005) 79:4700–8. doi:10.1128/JVI.79.8.4700-4708.2005 
22. Ely KH, Cauley LS, Roberts AD, Brennan JW, Cookenham T, Woodland DL. 
Nonspecific recruitment of memory CD8+ T cells to the lung airways during 
respiratory virus infections. J Immunol (2003) 170:1423–9. doi:10.4049/
jimmunol.170.3.1423 
23. Walch JM, Zeng Q, Li Q, Oberbarnscheidt MH, Hoffman RA, Williams AL, 
et al. Cognate antigen directs CD8+ T cell migration to vascularized trans-
plants. J Clin Invest (2013) 123:2663–71. doi:10.1172/JCI66722 
24. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dys-
regulation. Annu Rev Immunol (2005) 23:447–85. doi:10.1146/annurev.
immunol.23.021704.115643 
25. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, et al. 
T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autono-
mous event. Immunity (2009) 31:643–53. doi:10.1016/j.immuni.2009.07.008 
26. Calderon B, Carrero JA, Miller MJ, Unanue ER. Cellular and molecular events 
in the localization of diabetogenic T cells to islets of Langerhans. Proc Natl 
Acad Sci U S A (2011) 108:1561–6. doi:10.1073/pnas.1018973108 
27. Calderon B, Carrero JA, Miller MJ, Unanue ER. Entry of diabetogenic T cells 
into islets induces changes that lead to amplification of the cellular response. 
Proc Natl Acad Sci U S A (2011) 108:1567–72. doi:10.1073/pnas.1018975108 
October 2015 | Volume 6 | Article 5046
Zhang and Lakkis Memory T cell migration
Frontiers in Immunology | www.frontiersin.org
28. Laudanna C, Kim JY, Constantin G, Butcher E. Rapid leukocyte 
integrin activation by chemokines. Immunol Rev (2002) 186:37–46. 
doi:10.1034/j.1600-065X.2002.18604.x 
29. Burbach BJ, Medeiros RB, Mueller KL, Shimizu Y. T-cell receptor signaling to inte-
grins. Immunol Rev (2007) 218:65–81. doi:10.1111/j.1600-065X.2007.00527.x 
30. Smith A, Stanley P, Jones K, Svensson L, McDowall A, Hogg N. The role of the 
integrin LFA-1 in T-lymphocyte migration. Immunol Rev (2007) 218:135–46. 
doi:10.1111/j.1600-065X.2007.00537.x 
31. Archambault AS, Sim J, Gimenez MA, Russell JH. Defining antigen-depen-
dent stages of T cell migration from the blood to the central nervous system 
parenchyma. Eur J Immunol (2005) 35:1076–85. doi:10.1002/eji.200425864 
32. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidi-
rectional signaling. Annu Rev Cell Dev Biol (2005) 21:381–410. doi:10.1146/
annurev.cellbio.21.090704.151217 
33. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological 
synapse. Curr Opin Cell Biol (2012) 24:107–15. doi:10.1016/j.ceb.2011.10.004 
34. Wang H, Lim D, Rudd CE. Immunopathologies linked to integrin signalling. 
Semin Immunopathol (2010) 32:173–82. doi:10.1007/s00281-010-0202-3 
35. Ward SG, Marelli-Berg FM. Mechanisms of chemokine and antigen-depen-
dent T-lymphocyte navigation. Biochem J (2009) 418:13–27. doi:10.1042/
BJ20081969 
36. Kinashi T. Intracellular signalling controlling integrin activation in lympho-
cytes. Nat Rev Immunol (2005) 5:546–59. doi:10.1038/nri1646 
37. Montresor A, Toffali L, Constantin G, Laudanna C. Chemokines and the 
signaling modules regulating integrin affinity. Front Immunol (2012) 3:127. 
doi:10.3389/fimmu.2012.00127 
38. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, et al. 
CalDAG-GEFI integrates signaling for platelet aggregation and thrombus 
formation. Nat Med (2004) 10:982–6. doi:10.1038/nm1098 
39. Katagiri K, Maeda A, Shimonaka M, Kinashi T. RAPL, a Rap1-binding 
molecule that mediates Rap1-induced adhesion through spatial regulation of 
LFA-1. Nat Immunol (2003) 4:741–8. doi:10.1038/ni950 
40. Laudanna C, Campbell JJ, Butcher EC. Role of Rho in chemoattractant-ac-
tivated leukocyte adhesion through integrins. Science (1996) 271:981–3. 
doi:10.1126/science.271.5251.981 
41. Slater SJ, Seiz JL, Stagliano BA, Stubbs CD. Interaction of protein kinase C 
isozymes with Rho GTPases. Biochemistry (2001) 40:4437–45. doi:10.1021/
bi001654n 
42. Giagulli C, Scarpini E, Ottoboni L, Narumiya S, Butcher EC, Constantin G, 
et al. RhoA and zeta PKC control distinct modalities of LFA-1 activation by 
chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo 
homing. Immunity (2004) 20:25–35. doi:10.1016/S1074-7613(03)00350-9 
43. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskel-
eton: molecular hardware for T cell signaling. Nat Immunol (2000) 1:23–9. 
doi:10.1038/76877 
44. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, 
et  al. The immunological synapse. Annu Rev Immunol (2001) 19:375–96. 
doi:10.1146/annurev.immunol.19.1.375 
45. Kupfer A, Kupfer H. Imaging immune cell interactions and functions: 
SMACs and the Immunological Synapse. Semin Immunol (2003) 15:295–300. 
doi:10.1016/j.smim.2003.09.001 
46. Zhang W, Sommers CL, Burshtyn DN, Stebbins CC, DeJarnette JB, Trible RP, 
et al. Essential role of LAT in T cell development. Immunity (1999) 10:323–32. 
doi:10.1016/S1074-7613(00)80032-1 
47. De Franceschi L, Scardoni G, Tomelleri C, Danek A, Walker RH, Jung HH, 
et al. Computational identification of phospho-tyrosine sub-networks related 
to acanthocyte generation in neuroacanthocytosis. PLoS One (2012) 7:e31015. 
doi:10.1371/journal.pone.0031015 
48. Katagiri K, Shimonaka M, Kinashi T. Rap1-mediated lymphocyte function-as-
sociated antigen-1 activation by the T cell antigen receptor is dependent on 
phospholipase C-gamma1. J Biol Chem (2004) 279:11875–81. doi:10.1074/jbc.
M310717200 
49. Singer AL, Bunnell SC, Obstfeld AE, Jordan MS, Wu JN, Myung PS, et  al. 
Roles of the proline-rich domain in SLP-76 subcellular localization and T cell 
function. J Biol Chem (2004) 279:15481–90. doi:10.1074/jbc.M313339200 
50. Beach D, Gonen R, Bogin Y, Reischl IG, Yablonski D. Dual role of SLP-76 in 
mediating T cell receptor-induced activation of phospholipase C-gamma1. J 
Biol Chem (2007) 282:2937–46. doi:10.1074/jbc.M606697200 
51. Geng L, Raab M, Rudd CE. Cutting edge: SLP-76 cooperativity with 
FYB/FYN-T in the up-regulation of TCR-driven IL-2 transcription 
requires SLP-76 binding to FYB at Tyr595 and Tyr651. J Immunol (1999) 
163:5753–7. 
52. Geng L, Pfister S, Kraeft SK, Rudd CE. Adaptor FYB (Fyn-binding protein) 
regulates integrin-mediated adhesion and mediator release: differential 
involvement of the FYB SH3 domain. Proc Natl Acad Sci U S A (2001) 
98:11527–32. doi:10.1073/pnas.191378198 
53. Tian J, Pabst O, Romermann D, Skubich S, Forster R, Beckmann J, et  al. 
Inactivation of T-cell receptor-mediated integrin activation prolongs 
allograft survival in ADAP-deficient mice. Transplantation (2007) 84:400–6. 
doi:10.1097/01.tp.0000269724.06142.92 
54. Liu J, Kang H, Raab M, da Silva AJ, Kraeft SK, Rudd CE. FYB (FYN binding 
protein) serves as a binding partner for lymphoid protein and FYN kinase 
substrate SKAP55 and a SKAP55-related protein in T cells. Proc Natl Acad Sci 
U S A (1998) 95:8779–84. doi:10.1073/pnas.95.15.8779 
55. Marie-Cardine A, Hendricks-Taylor LR, Boerth NJ, Zhao H, Schraven B, 
Koretzky GA. Molecular interaction between the Fyn-associated protein 
SKAP55 and the SLP-76-associated phosphoprotein SLAP-130. J Biol Chem 
(1998) 273:25789–95. doi:10.1074/jbc.273.40.25789 
56. Kliche S, Breitling D, Togni M, Pusch R, Heuer K, Wang X, et al. The ADAP/
SKAP55 signaling module regulates T-cell receptor-mediated integrin 
activation through plasma membrane targeting of Rap1. Mol Cell Biol (2006) 
26:7130–44. doi:10.1128/MCB.00331-06 
57. Jo EK, Wang H, Rudd CE. An essential role for SKAP-55 in LFA-1 clustering on 
T cells that cannot be substituted by SKAP-55R. J Exp Med (2005) 201:1733–9. 
doi:10.1084/jem.20042577 
58. Raab M, Wang H, Lu Y, Smith X, Wu Z, Strebhardt K, et al. T cell receptor 
“inside-out” pathway via signaling module SKAP1-RapL regulates T cell 
motility and interactions in lymph nodes. Immunity (2010) 32:541–56. 
doi:10.1016/j.immuni.2010.03.007 
59. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic 
tolerance. J Am Soc Nephrol (2003) 14:2402–10. doi:10.1097/01.
ASN.0000085020.78117.70 
60. Macedo C, Orkis EA, Popescu I, Elinoff BD, Zeevi A, Shapiro R, 
et  al. Contribution of naive and memory T-cell populations to the 
human alloimmune response. Am J Transplant (2009) 9:2057–66. 
doi:10.1111/j.1600-6143.2009.02742.x 
61. Li XC, Kloc M, Ghobrial RM. Memory T cells in transplantation – progress 
and challenges. Curr Opin Organ Transplant (2013) 18:387–92. doi:10.1097/
MOT.0b013e3283626130 
62. Selin LK, Cornberg M, Brehm MA, Kim SK, Calcagno C, Ghersi D, et al. CD8 
memory T cells: cross-reactivity and heterologous immunity. Semin Immunol 
(2004) 16:335–47. doi:10.1016/j.smim.2004.08.014 
63. Amir AL, D’Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer 
R, et  al. Allo-HLA reactivity of virus-specific memory T cells is common. 
Blood (2010) 115:3146–57. doi:10.1182/blood-2009-07-234906 
64. Krummey SM, Ford ML. Heterogeneity within T Cell memory: implica-
tions for transplant tolerance. Front Immunol (2012) 3:36. doi:10.3389/
fimmu.2012.00036 
65. Page AJ, Ford ML, Kirk AD. Memory T-cell-specific therapeutics in organ 
transplantation. Curr Opin Organ Transplant (2009) 14:643–9. doi:10.1097/
MOT.0b013e328332bd4a 
66. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, 
et al. A phase I/II randomized open-label multicenter trial of efalizumab, a 
humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 
(2007) 7:1770–7. doi:10.1111/j.1600-6143.2007.01845.x 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Zhang and Lakkis. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
